Head to Head Review: Chromocell Therapeutics (CHRO) and Its Peers

Chromocell Therapeutics (NYSE:CHRO) is one of 300 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its peers? We will compare Chromocell Therapeutics to related businesses based on the strength of its dividends, analyst recommendations, profitability, earnings, institutional ownership, risk and valuation.

Analyst Recommendations

This is a summary of current ratings and target prices for Chromocell Therapeutics and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chromocell Therapeutics	0	0	1	0	3.00
Chromocell Therapeutics Competitors	1980	5478	14091	306	2.58

As a group, “Biological products, except diagnostic” companies have a potential upside of 115.73%. Given Chromocell Therapeutics’ peers higher possible upside, analysts clearly believe Chromocell Therapeutics has less favorable growth aspects than its peers.

Risk and Volatility

Chromocell Therapeutics has a beta of 4.59, indicating that its stock price is 359% more volatile than the S&P 500. Comparatively, Chromocell Therapeutics’ peers have a beta of -4.50, indicating that their average stock price is 550% less volatile than the S&P 500.

Institutional & Insider Ownership

78.0% of Chromocell Therapeutics shares are held by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 16.4% of Chromocell Therapeutics shares are held by insiders. Comparatively, 15.6% of shares of all “Biological products, except diagnostic” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Chromocell Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Chromocell Therapeutics	N/A	N/A	-453.90%
Chromocell Therapeutics Competitors	-2,185.76%	-161.46%	-40.62%

Earnings and Valuation

This table compares Chromocell Therapeutics and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Chromocell Therapeutics	N/A	-$7.38 million	-0.81
Chromocell Therapeutics Competitors	$575.37 million	-$70.96 million	-1.97

Chromocell Therapeutics’ peers have higher revenue, but lower earnings than Chromocell Therapeutics. Chromocell Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Chromocell Therapeutics beats its peers on 9 of the 13 factors compared.

Chromocell Therapeutics Company Profile

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.